Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 16/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1875797 | 1.00 | HRH3 (0.54) | HRH3NPC1RAB9AALDH1A1CYP2D6 | |
| SCHEMBL28966903 | 0.78 | CYP2D6 (0.63) | HRH3ALDH1A1CYP2D6KCNH2 | |
| SCHEMBL3633820 | 0.77 | CYP2D6 (0.53) | ALDH1A1CYP2D6POLB | |
| SCHEMBL3633822 | 0.77 | CYP2D6 (0.53) | ALDH1A1CYP2D6POLB | |
| SCHEMBL30301983 | 0.77 | CYP2D6 (0.55) | ALDH1A1CYP2D6POLBKCNH2 | |
| SCHEMBL28414380 | 0.76 | CYP2D6 (0.64) | NPC1RAB9AALDH1A1CYP2D6POLB | |
| SCHEMBL28966921 | 0.76 | CYP2D6 (0.59) | HRH3ALDH1A1CYP2D6 | |
| SCHEMBL1431545 | 0.76 | ALDH1A1 (0.55) | HRH3ALDH1A1CYP2D6POLB | |
| SCHEMBL3631591 | 0.76 | ALDH1A1 (0.55) | HRH3ALDH1A1CYP2D6POLB | |
| SCHEMBL1431546 | 0.76 | ALDH1A1 (0.55) | HRH3ALDH1A1CYP2D6POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2300422-B1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2014-11-05 | — | — | EP | disclosed |
| US-20110105459-A1 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105459-A1 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | HRH4, HRH3, HRH1 | HRH3 2/4885NPC1 2956/4885RAB9A 1843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.